
vTv Therapeutics (VTVT) Stock Forecast & Price Target
vTv Therapeutics (VTVT) Analyst Ratings
Bulls say
vTv Therapeutics Inc has a promising financial outlook primarily due to its innovative clinical pipeline, particularly with cadisegliatin (TTP399), which is positioned as the only oral adjunctive therapy in late-stage development for type 1 diabetes (T1D). An increase in the estimated peak market penetration from 20% to 25% significantly enhances the company's risk-adjusted discounted cash flow (DCF) valuation and reflects a growing long-term conviction in the potential of cadisegliatin for treating T1D and potentially type 2 diabetes (T2D). Positive key metrics from ongoing studies, including management's reviews and insights from related research, bolster confidence in the clinical success of their drug candidates and their ability to capture substantial market share amid a growing demand for more convenient diabetes treatments.
Bears say
vTv Therapeutics faces significant challenges due to the historical issues seen with first-generation glucokinase activators (GKAs), which have consistently demonstrated problems such as excess hypoglycemia, worsening lipid profiles, and diminishing efficacy over time, leading to increased safety concerns. The company’s lead candidate, cadisegliatin (TTP399), aims to address these limitations, yet it remains in late-stage development and is subject to risks associated with slower patient enrollment and potentially disappointing safety and efficacy outcomes. Additionally, with nearly 80% of adults with type 1 diabetes failing to meet key glucose control goals, there exists a fundamental clinical ceiling for improved therapeutic outcomes, which poses an ongoing risk to vTv Therapeutics' commercial prospects.
This aggregate rating is based on analysts' research of vTv Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
vTv Therapeutics (VTVT) Analyst Forecast & Price Prediction
Start investing in vTv Therapeutics (VTVT)
Order type
Buy in
Order amount
Est. shares
0 shares